Relay Therapeutics (RLAY) Operating Margin (2021 - 2026)
Relay Therapeutics (RLAY) reported Operating Margin of 2619.67% for Q1 2026, down 151446.0% year-over-year from N/an in Q1 2025, and down 202.45% quarter-over-quarter from 866.14% in Q4 2025.
Relay Therapeutics (RLAY) Operating Margin (2021 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has 6 years of Operating Margin data on file, last reported at 2619.67% in Q1 2026.
- Operating Margin for Q1 2026 came in at 2619.67%, down 151446.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 2776.6% (up 200233.0% YoY), and the FY2025 annual result was 1971.59%, up 175048.0% from the prior year.
- Operating Margin retreated to 2619.67% in Q1 2026 per RLAY's latest filing, from 866.14% in the prior quarter.
- Over five years, Operating Margin peaked at 9219600.0% in Q4 2023 and troughed at 89117.65% in Q2 2023.
- A 5-year average of 690655.84% and a median of 11351.11% in 2025 frame the typical range for Operating Margin.
- On a YoY basis, Operating Margin climbed as much as 924839486 bps in 2023 and fell as far as 6779956 bps in 2023.
- A 5-year view of Operating Margin shows it stood at 28794.86% in 2022, then soared by 32118 bps to 9219600.0% in 2023, then plunged by 100 bps to 903.0% in 2024, then rose by 4 bps to 866.14% in 2025, then sank by 202 bps to 2619.67% in 2026.
- Business Quant data shows RLAY's Operating Margin at 2619.67% in Q1 2026, 866.14% in Q4 2025, and 11351.11% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Relay Therapeutics | 2.86 Bn | 2.86 Bn | - | -2,619.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,619.67% |
| Dec 31, 2025 | -866.14% |
| Jun 30, 2025 | -11,351.11% |
| Mar 31, 2025 | -1,105.21% |
| Mar 31, 2024 | -903.00% |
| Dec 31, 2023 | 9,219,600.00% |
| Sep 30, 2023 | -291.95% |
| Jun 30, 2023 | -89,117.65% |
| Mar 31, 2023 | -44,768.58% |
| Dec 31, 2022 | -28,794.86% |
| Sep 30, 2022 | -24,968.60% |
| Jun 30, 2022 | -21,318.08% |
| Mar 31, 2022 | -14,969.21% |
| Dec 31, 2021 | -11,944.09% |
| Sep 30, 2021 | -9,157.66% |
| Jun 30, 2021 | -22,936.02% |
| Mar 31, 2021 | -4,454.31% |